Among patients with FLT3-internal tandem repeats, sorafenib maintenance therapy reduces the risk of relapse and death after allo-HSCT.
Researchers studied the pros and cons of transplantation from different donor sources to enhance overall outcomes of allo-HSCT in adults with T-cell malignancies.
Ibrutinib-mediated macrophage inhibition may underlie an increased risk of invasive fungal infection in patients with CLL treated with this agent.
Obinutuzumab plus venetoclax was associated with improved outcomes compared with obinutuzumab plus chlorambucil, regardless of the presence of unfavorable genetic prognostic factors.
Researchers found that identifying and treating acute odontogenic disease before induction chemotherapy prevented infectious dental emergencies in AML patients.